Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994


  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011


Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 



Lowery, WJ, Gehrig, PA, Ko, E, Secord, AA, Chino, J, and Havrilesky, LJ. "Surgical staging for endometrial cancer in the elderly - is there a role for lymphadenectomy?." Gynecol Oncol 126, no. 1 (July 2012): 12-15.

Full Text

Laskey, RA, Poniewierski, MS, Lopez, MA, Hanna, RK, Secord, AA, Gehrig, PA, Lyman, GH, and Havrilesky, LJ. "Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer." Gynecol Oncol 125, no. 3 (June 2012): 625-630.

Full Text

Zighelboim, I, Wright, JD, Gao, F, Case, AS, Massad, LS, Mutch, DG, Powell, MA, Thaker, PH, Eisenhauer, EL, Cohn, DE, Valea, FA, Secord, AA, Lippmann, LT, and Rader, JS. "Phase II trial of topotecan, cisplatin, and bevacizumab for recurrent or persistent cervical cancer." May 20, 2012.


Chino, JP, Jones, E, Berchuck, A, Secord, AA, and Havrilesky, LJ. "The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer." Int J Radiat Oncol Biol Phys 82, no. 5 (April 1, 2012): 1872-1879.

Full Text

Teoh, D, and Secord, AA. "Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer." International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society 22, no. 3 (March 2012): 348-359. (Review)

Full Text

Berchuck, A, Secord, AA, and Havrilesky, LJ. "Minimally invasive surgery for endometrial cancer: the horse is already out of the barn." J Clin Oncol 30, no. 7 (March 1, 2012): 681-682.

Full Text

Havrilesky, LJ, Pokrzywinski, R, Revicki, D, Higgins, RV, Nycum, LR, Kohler, MF, Berchuck, A, Myers, ER, and Secord, AA. "Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer." Cancer 118, no. 2 (January 15, 2012): 386-391.

Full Text

Edwards, JM, Lowery, WJ, and Secord, AA. "Quinary debulking for epithelial ovarian cancer." Journal of surgical case reports 2012, no. 7 (January 2012): 7-.

Full Text

Lowery, WJ, Gehrig, PA, Ko, E, Secord, AA, Chino, J, and Havrilesky, LJ. "Surgical staging for endometrial cancer in the elderly - Is there a role for lymphadenectomy?." Obstetrical and Gynecological Survey 67, no. 11 (2012): 702-703.

Full Text

Pokrzywinski, R, Secord, AA, Havrilesky, LJ, Puls, LE, Holloway, RW, Lewandowski, GS, Higgins, RV, Nycum, LR, Kohler, MF, and Revicki, DA. "Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial." Gynecol Oncol 123, no. 3 (December 2011): 505-510.

Full Text